2019年孕早期药物流产的提供情况:加拿大堕胎提供者调查结果
Provision of first-trimester medication abortion in 2019: Results from the Canadian abortion provider survey.
作者信息
Ennis Madeleine, Renner Regina, Guilbert Edith, Norman Wendy V, Pymar Helen, Kean Lauren, Carson Andrea, Martin-Misener Ruth, Dunn Sheila
机构信息
Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada; Contraception Abortion Research Team, Women's Health Research Institute, BC Women's Hospital and Health Centre, Vancouver, BC, Canada.
Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC, Canada; Contraception Abortion Research Team, Women's Health Research Institute, BC Women's Hospital and Health Centre, Vancouver, BC, Canada.
出版信息
Contraception. 2022 Sep;113:19-25. doi: 10.1016/j.contraception.2022.03.020. Epub 2022 Mar 26.
OBJECTIVE
To explore the Canadian first-trimester medication abortion (MA) workforce and their clinical care following the introduction of mifepristone in 2017, updated national clinical practice guidelines and government approval of nurse practitioners (NPs) as first-trimester MA providers.
STUDY DESIGN
We conducted a national, self-administered, cross-sectional survey of abortion providers in 2019. Our bilingual (French/English) survey collected information on demographics, abortion number, and clinical care characteristics. The true number of abortion providers is unknown thus we cannot calculate a survey response rate. To maximize identification of possibly eligible respondents, we widely distributed the survey between July and December 2020 through health professional organizations, using a modified Dillman technique. We used descriptive statistics to characterize the workforce and clinical practices.
RESULTS
Four-hundred-sixty-five clinicians responded, of whom 388 provided first-trimester MA. Physicians (n = 358) and NPs (n = 30) reported providing 13,429 first-trimester MAs in 2019 which represented 27.7% of all reported abortions in the survey. The majority of first-trimester MA respondents were primary care physicians (n = 245, 63.1%), had less than five years' experience (n = 223, 61.3%) and practiced outside of hospitals (n = 228, 66.5%). Forty-three percent (n = 165) practiced rurally, and 44.0% (n = 136) used telemedicine for some abortion care. Ninety-nine percent (n = 350) used a guideline-recommended mifepristone/misoprostol regimen while 14.5% (n = 51) sometimes used methotrexate. Patients most commonly received mifepristone/misoprostol at community pharmacies (median 100.0%; interquartile range 50.0%-100.0%).
CONCLUSION
Our results suggest that there are many new first-trimester MA providers, an increase in the proportion of MAs since 2012 and a shift to primary care settings. Respondents widely adopted mifepristone.
IMPLICATIONS STATEMENT
Our results highlight that, following mifepristone introduction, many new primary care practitioners started providing first-trimester medication abortion throughout Canada, including the first non-physicians. This increased access to abortion particularly in rural and underserved communities. These results could inform future directions in policy, guidelines, and abortion access initiatives.
目的
探讨2017年米非司酮引入后、更新的国家临床实践指南以及政府批准执业护士(NP)作为孕早期药物流产(MA)提供者后,加拿大孕早期药物流产的医疗服务人员及其临床护理情况。
研究设计
2019年,我们对流产提供者进行了一项全国性的、自行填写的横断面调查。我们的双语(法语/英语)调查问卷收集了人口统计学、流产次数和临床护理特征方面的信息。流产提供者的实际数量未知,因此我们无法计算调查回复率。为了最大限度地识别可能符合条件的受访者,我们在2020年7月至12月期间通过卫生专业组织广泛分发了调查问卷,采用了改良的迪尔曼技术。我们使用描述性统计来描述医疗服务人员和临床实践情况。
结果
465名临床医生回复了问卷,其中388人提供孕早期药物流产服务。医生(n = 358)和执业护士(n = 30)报告在2019年提供了13429例孕早期药物流产,占调查中所有报告流产的27.7%。大多数孕早期药物流产的受访者是初级保健医生(n = 245,63.1%),经验不足五年(n = 223,61.3%),且在医院外执业(n = 228,66.5%)。43%(n = 165)在农村地区执业,44.0%(n = 136)在某些流产护理中使用了远程医疗。99%(n = 350)使用了指南推荐的米非司酮/米索前列醇方案,而14.5%(n = 51)有时使用甲氨蝶呤。患者最常在社区药房接受米非司酮/米索前列醇(中位数为100.0%;四分位间距为50.0% - 100.0%)。
结论
我们的结果表明,有许多新的孕早期药物流产提供者,自2012年以来药物流产的比例有所增加,并且服务地点转向了初级保健机构。受访者广泛采用了米非司酮。
启示声明
我们的结果突出表明,在引入米非司酮后,许多新的初级保健从业者开始在加拿大各地提供孕早期药物流产服务,包括首批非医生从业者。这增加了流产服务的可及性,尤其是在农村和服务不足的社区。这些结果可为未来政策、指南和流产服务可及性倡议的方向提供参考。